Phase II Trial of Cabozantinib Plus Erlotinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer with Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) User montaukwhaler, in the non small cell lung cancer subreddit, 20 Feb 2019